r Concurrent 5-HT 2A (Q pathway) and 5-HT 7 (S pathway) serotonin receptor activation cancels phrenic motor facilitation due to mutual cross-talk inhibition.
Introduction
Moderate acute intermittent hypoxia (AIH) elicits longlasting serotonin-dependent phrenic motor plasticity, an effect known as phrenic long-term facilitation (pLTF) (Millhorn et al. 1980; Mitchell et al. 2001; Baker-Herman et al. 2004; Navarrete-Opazo et al. 2015; Navarrete-Opazo et al. 2017) . Pharmacological activation of spinal serotonin receptors in the absence of hypoxia elicits similar forms of phrenic motor facilitation (pMF) through multiple, distinct cellular cascades. pMF is a more general term used to describe all types of phrenic motor plasticity, including AIH-induced pLTF. For instance, whereas Gq protein-coupled serotonin receptor activation elicits pMF by a mechanism that requires ERK-MAP kinase signalling and new brain-derived neurotrophic factor (BDNF) protein synthesis (Baker-Herman et al. 2004; Hoffman et al. 2012) , Gs protein-coupled receptor activation elicits pMF and requires Akt (not ERK) signalling, and new TrkB (not BDNF) protein synthesis (Golder et al. 2008; Hoffman & Mitchell, 2011) . Because multiple Gq and Gs protein-coupled receptors elicit phrenic motor plasticity, we refer to these cellular mechanisms as the Q and S pathways to pMF, respectively. Surprisingly, although the Q and S pathways each elicit pMF when acting alone, co-activation cancels pMF, revealing powerful inhibitory cross-talk interactions that limit the capacity for serotonin-dependent phrenic motor plasticity Hoffman & Mitchell, 2013; Perim et al. 2018) . With unequal activation, such as during moderate AIH, S pathway inhibition allows full Q pathway expression and enhanced pLTF Hoffman & Mitchell, 2013; Navarrete-Opazo & Mitchell, 2014) . The mechanisms of S to Q pathway inhibition have been investigated; for example, spinal inhibition of serotonin type 7 receptors (5-HT 7 ) or protein kinase A (PKA) enhances 5-HT 2 receptor-dependent, moderate AIH-induced pLTF (Hoffman & Mitchell, 2013 ) and 5-HT 2 A and B (5-HT 2A/2B ) receptor-dependent pMF Perim et al. 2018) .
The mechanisms of Q to S cross-talk inhibition are less well known. NADPH oxidase activity is necessary for 5-HT 2 receptor-dependent pLTF following moderate AIH , and spinal 5-HT 2B (not 5-HT 2A ) receptor-induced pMF (MacFarlane et al. 2011; Perim et al. 2018) . Furthermore, NADPH oxidase activity plays an essential role in inhibitory cross-talk from 5-HT 2B to 5-HT 7 receptor-induced pMF . The role of NADPH oxidase activity in 5-HT 2A to 5-HT 7 cross-talk inhibition has not been investigated. NADPH oxidase generates superoxide anions that are rapidly converted to hydrogen peroxide (Nauseef, 2014) . Because hydrogen peroxide may undermine Gs protein-coupled adenylyl cyclase activity necessary for 5-HT 7 receptor-induced pMF, we originally hypothesized that NADPH oxidase also underlies 5-HT 2A to 5-HT 7 cross-talk inhibition, similar to 5-HT 2B and 5-HT 7 receptor interactions .
There were several original hypotheses behind this study: (1) concurrent spinal 5-HT 2A and 5-HT 7 receptor activation does not elicit pMF due to cross-talk inhibition between these distinct pMF triggers; (2) 5-HT 7 receptor-induced PKA activation constrains 5-HT 2A -induced pMF, confirming previous reports from our laboratory ; and (3) 5-HT 2A -induced NADPH oxidase activation constrains 5-HT 7 -induced pMF. Although PKA inhibition reveals pMF with concurrent 5-HT 2A and 5-HT 7 receptor activation, NADPH oxidase inhibition had no effect, contrary to expectations. Thus, we sought alternative mechanisms to explain the Q to S cross-talk constraint.
Activation of a novel protein kinase C (PKC) isoform (PKCθ) is necessary for AIH-induced, 5-HT 2 -dependent pLTF (Devinney et al. 2015) . On the other hand, unidentified PKC isoforms distinct from PKCθ are sufficient to induce pMF (Devinney & Mitchell, 2018) , consistent with the idea that Gq protein activation upregulates multiple PKC isoforms through 'accessory divergent signalling' (Nishizuka, 1984 (Nishizuka, , 1992 Narla et al. 2015) . Certain PKC isoforms constrain adenylyl cyclase activity (Lai et al. 1997; Lin et al. 2002) , potentially decreasing the cAMP formation necessary for the S pathway to pMF. Thus, we tested the hypothesis that PKC activation downstream from 5-HT 2A receptor activation constrains 5-HT 7 -induced pMF, accounting for this form of Q to S pathway inhibition. Multiple PKC inhibitors with different specificity were used to identify the relevant PKC isoform. As spinal PKCδ inhibition restored pMF with concurrent 5-HT 2A and 5-HT 7 activation, we tested the hypothesis that spinal PKCδ inhibition would enhance another example of S pathway-dependent pMF elicited by intermittent hypoxia: adenosine 2A (A2A) receptor-dependent pLTF following severe AIH . Beyond demonstrating a specific molecule necessary for Q to S pathway inhibition, our results also suggest that this molecule constrains severe AIH-induced pLTF. By preventing cross-talk inhibition, we can optimize phrenic motor plasticity.
Methods

Ethical approval
A total of 112 adult male Sprague Dawley rats (208A Colony, Envigo, IN, USA; 300-400 g, ß3.5 months old) were used in this study. Rats were housed in pairs and maintained on a 12:12 h light/dark cycle with access to food and water ad libitum. The University of Florida Institutional Animal Care and Use Committee approved all experimental procedures (protocol #201408657), and they were conducted in accordance with the Animal Welfare Act, the Public Health Service Policy on Hyman Care and Use of Laboratory Animals, and the NIH Guide for the Care and Use of Laboratory Animals (2011). The investigators understand the ethical principles followed by The Journal of Physiology, and their work complies with the Journal's animal ethics checklist (Grundy, 2015) .
Neurophysiological experiments
Rats were induced in a closed chamber with 3% isoflurane mixed in 100% O 2 at ß2.5 l/min, and then transferred to a heated surgical table. Rectal temperature was maintained at 37.5 ± 1°C. After maintenance of anaesthesia with a nose cone, rats were tracheotomized and pump-ventilated (Rodent Ventilator, model 683; Harvard Apparatus, South Natick, MA, USA) with an inspiratory mixture of 60% O 2 , 2% CO 2 , balanced with N 2 (tidal volume 2.5 ml at 70 breaths/min). Tracheal pressure was continuously monitored, and the lungs were hyperinflated approximately once every 30 min to minimize alveolar collapse by briefly occluding the expiratory line; this continued until starting an experimental protocol. Vagus nerves were isolated in the mid-cervical region and cut to avoid entrainment of ventilatory efforts with the ventilator. End-tidal CO 2 was monitored throughout surgery procedures with a flow-through capnograph with sufficient response time to detect end-tidal CO 2 
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levels in a rat (Capnogard ETCO 2 monitor, Novametrix, Wallingford, CT, USA). Anaesthesia was slowly converted from isoflurane to urethane (2.1 g/kg) injected through a tail vein catheter (24 Gauge; Surflash, Somerset, NJ, USA); the rat was weaned from isoflurane over ß20 min. Adequate levels of anaesthesia were confirmed by absence of the withdrawal reflex and blood pressure response to toe pinch. Once conversion to urethane was complete, at least 1 h was allowed for isoflurane to dissipate before starting an experimental protocol. Intravenous fluid infusions were administered continuously and adjusted as needed to maintain standard base excess status between −3.0 to 3.0 mmol/l [1-3 ml/h; 20% NaHCO 3 solution (8.4%; Hospira, Lake Forest, IL, USA) and 80% lactated Ringer solution (Vedco, Saint Joseph, MO, USA)]. The femoral artery was catheterized with a polyethylene catheter to record blood pressure (Argon Pressure Transducer, DTXPlus, Plano, TX, USA) and to monitor arterial blood sampling (ABL 90 Flex, Radiometer, OH, USA) using a heparinized plastic capillary tube (electrolyte balanced 70 IU/ml; 70 μl; Radiometer). Rats were subject to neuromuscular blockade with the nicotinic acetylcholine receptor blocker, pancuronium bromide (3 mg/kg I.V.; Sigma-Aldrich, St Louis, MO, USA).
For intrathecal drug delivery, muscles overlying the dorsal aspect of the cervical spinal cord were separated to expose the C2 vertebrae. A C2 laminectomy was performed and the region was covered with cotton until a silicone catheter (2 French, 0.6 mm OD; Access Technologies, Skokie, IL, USA) attached to a 50 μl Hamilton syringe was inserted through a small hole into the dura matter. The catheter was advanced caudally (ß3 mm) until resting over the C3-C4 spinal region. A Hamilton repeating dispenser (PB600-1; Hamilton, Reno, NV, USA) was used for intrathecal drug delivery at ß6 μl/min injection rate.
The left phrenic and hypoglossal nerves were isolated via a dorsal approach, cut distally, desheathed and protected from desiccation with saline-soaked cotton until nerve recordings were initiated. Nerve activity was recorded using bipolar glass suction electrodes, placed in position using a micromanipulator (Narishige, Tokyo, Japan). Signals were acquired at 25,000 Hz sampling rate, 10,000× amplified, band-pass filtered (0.3-5 kHz; Model 1700, A-M Systems, Sequim, WA, USA), and digitized (CED 1401; Cambridge Electronic Design, Cambridge, UK) to a computer using Spike2 software (version 8; Cambridge
Electronic Design). Offline analyses were performed in rectified and smoothed (time-constant 0.05 s) signals.
Once nerve recording had stabilized, the CO 2 apnoeic threshold was determined by progressively lowering the inspired CO 2 fraction and/or increasing respiratory frequency until phrenic and hypoglossal nerve activity ceased; the recruitment threshold was then determined by raising the inspired CO 2 fraction until phrenic and hypoglossal nerve activity resumed. Baseline end-tidal CO 2 was maintained 2-3 mmHg above the recruitment threshold. Data were included in the analysis only if: (1) P aCO 2 was maintained within ±1.5 mmHg from baseline values; (2) the drop in mean arterial pressure from baseline to the end of experimental protocol was <30 mmHg; and (3) P aO 2 decreased <50 mmHg from baseline values and remained above 150 mmHg during the protocol. At the end of experiments, rats were killed via an overdose of urethane. PaCO 2 , mmHg Baseline 45 ± 2 4 4 ± 3 4 3 ± 3 4 4 ± 2 30 44 ± 2 4 4 ± 4 4 4 ± 3 4 4 ± 3 60 43 ± 2 4 4 ± 4 4 3 ± 3 4 5 ± 2 90 45 ± 2 4 4 ± 3 4 4 ± 3 4 6 ± 3 PaO 2 , mmHg Baseline 313 ± 12 311 ± 20 309 ± 21 293 ± 42 30 298 ± 22 295 ± 28 314 ± 8 298 ± 34 60 302 ± 24 283 ± 24 290 ± 13 296 ± 35 90 312 ± 19 267 ± 13 296 ± 15 289 ± 29 sBE, mmol Baseline 1.1 ± 0.9 1.7 ± 1.4 1.8 ± 0.6 1.1 ± 1.2 30 0.8 ± 1.0 1.5 ± 1.2 2.8 ± 0.6 2.0 ± 0.8 60 0.2 ± 0.6 0.9 ± 2.1 1.2 ± 0.8 
Drugs
The 5-HT 7 agonist (AS-19), 5-HT 2A agonist (4-Iodo-2,5-dimethoxyphenylisopropylamine, hydrochloride; DOI hydrochloride) and PKC inhibitors (Gö6983 and Gö6976) were obtained from Tocris Biosciences (Minneapolis, MN, USA); PKCδ peptide inhibitor (PKCδi) was obtained from AnaSpec (Fremont, CA, USA); PKA inhibitor (Rp-8-Br-cAMPS) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA); and NADPH oxidase inhibitor (apocynin) was obtained from Sigma-Aldrich. All drugs were initially dissolved in 100% DMSO, and aliquots of the stock solution were stored at −20°C. Stock solution concentrations are: 5-HT 2A agonist, 5 mM; 5-HT 7 agonist, 2 mM; NADPH oxidase, 50 mM; Gö6983, 40 mM; Gö6976, 1 mM; PKCδi, 890 μM. On the day of experiments, aliquots of stock solution were thawed and diluted in saline to the desired concentrations based on prior studies from our laboratory (MacFarlane et al. 2011; Devinney et al. 2015; .
Experimental protocols 5-HT 2A (100 μM) and 5-HT 7 agonists (10 μM) were administered (i.e. individually or combined) in three, 6 μl injections separated by 5-min intervals to test the effect of 5-HT 2A and 5-HT 7 co-activation on pMF. Rats were primed with PKA inhibitor (10 μl, 1 mM), NADPH oxidase inhibitor (12 μl, 600 μM) or PKC inhibitor (Gö6983; 12 μl, 10 mM) using a second intrathecal catheter 20 min before 5-HT 2A and 5-HT 7 co-activation to better understand the mechanisms giving rise to cross-talk inhibition. Hypoglossal nerve activity and respiratory frequency were assessed as internal controls for unintended drug diffusion to brainstem respiratory centres as done previously (Baker-Herman & Mitchell, 2002) . To investigate the specific PKC isoform giving rise to cross-talk inhibition, different rat groups were primed with 10 μl of 155, 310 or 620 nM Gö6976 (aselective PKCα and PKCβ inhibitor; Martiny- Baron et al. 1993) , or 10 μl of 25 or 50 μM PKCδi (Chen et al. 2001) . Limited dose-response curves were created, informed by reported half-maximal inhibitory concentration (IC 50 ) of the drugs from in vitro experiments (Table 1) . To evaluate the effects of the Q to S pathway inhibition on more physiological forms of respiratory motor plasticity, rats were primed with 50 μM PKCδi followed by severe AIH, consisting of three, 5-min isocapnic hypoxic episodes (F IO 2 : ß0.08, P aO 2 : 25-30 mmHg; 5-min intervals of baseline O 2 ).
Data analyses
All dependent variables were tested for normal distribution by visual inspection of histograms and normal probability plots. Integrated phrenic and hypoglossal burst amplitude was averaged over 60 s during baseline, and at 30, 60 and 90 min after intrathecal drug injections. For each rat, integrated burst amplitude was normalized as the percentage change from baseline. Comparisons between and within groups were made using a mixed two-way ANOVA design with repeated measures for time. An independent t-test was used to compare pLTF magnitude 90 min after severe AIH between groups. When overall differences were indicated, individual groups/times were compared using Tukey's post hoc procedure. Values are expressed as mean ±1 standard error of the mean, J Physiol 597.2 unless otherwise specified. Differences were considered significant at P < 0.05.
Results
Effect of 5-HT 2A and 5-HT 7 co-activation on pMF Figure 1 shows representative traces of phrenic (A) and hypoglossal nerve recordings (B) from the same rats treated with vehicle, 5-HT 2A , 5-HT 7 or combined 5-HT 2A and 5-HT 7 agonists. Phrenic burst amplitude was increased relative to baseline (i.e. pMF) at 30, 60 and 90 min after spinal 5-HT 2A or 5-HT 7 activation alone (P < 0.05); pMF magnitude was 63 ± 19% and 61 ± 11% at 90 min after 5-HT 2A or 5-HT 7 agonist injections, respectively. Conversely, simultaneous 5-HT 2A and 5-HT 7 receptor activation failed to elicit pMF at any time evaluated ( Fig. 1C ; P > 0.05), demonstrating powerful inhibitory interactions between these serotonin receptor subtypes. Phrenic burst amplitude was stable throughout experimental protocols in vehicle-treated rats. Respiratory frequency and hypoglossal burst amplitude remained stable throughout recordings ( Figs 1D, E) , consistent with a lack of drug effects at the level of the brainstem. P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from each group at baseline, and 30, 60 and 90 min after injections are reported in Table 2 .
To ensure similar conditions among experimental groups during baseline, raw phrenic amplitude and end-tidal CO 2 at apnoeic and recruitment threshold were evaluated. Phrenic amplitude was similar among groups during baseline (Fig. 2A) . End-tidal CO 2 levels at apnoeic and recruitment thresholds were also similar among groups (Fig. 2B ).
Mechanism of cross-talk inhibition from 5-HT 7 to 5-HT 2A activation
To test the hypothesis that 5-HT 7 -induced PKA activation constrains 5-HT 2A -induced pMF, rats were pretreated with 
sBE, standard base excess; MAP, mean arterial pressure.
a PKA inhibitor followed by concurrent spinal 5-HT 2A and 5-HT 7 agonists or vehicle injections. Figure 3A shows representative traces of one animal from each experimental group. The PKA inhibitor was sufficient to partially rescue pMF at 90 min after spinal 5-HT 2A and 5-HT 7 co-activation (33 ± 8%; P < 0.05; Fig. 3B ). PKA inhibition did not impact pMF elicited by either 5-HT 2A or 5-HT 7 -receptor agonists alone, consistent with previous reports. No changes in phrenic burst amplitude (Fig. 3B ) or respiratory frequency (Fig. 3C ) were observed after PKA inhibitor delivery in vehicle-treated rats. P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from each group at baseline, and 30, 60 and 90 min after injections are reported in Table 3 .
Mechanism of cross-talk inhibition from 5-HT 2A to 5-HT 7 activation
To test the hypothesis that 5-HT 2A receptor-induced NADPH oxidase activation constrains 5-HT 7 -induced pMF, rats were pretreated with apocynin followed by spinal 5-HT 2A and 5-HT 7 agonists or vehicle injections. Figure 4A shows representative traces of one rat from each group. Inhibitory cross-talk interactions induced by 5-HT 2A and 5-HT 7 co-activation were not relieved by NADPH oxidase inhibition (P > 0.05; Fig. 4B ). Similar results were obtained when a higher apocynin dose was used (i.e. 1 mM vs. 600 μM; n = 1). Changes in phrenic burst amplitude (Fig. 4B ) or respiratory frequency (Fig. 4C) were not observed after apocynin administration in vehicle-treated rats. P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from each group at baseline, and 30, 60 and 90 min after injections are shown in Table 4 . To test the hypothesis that 5-HT 2A receptor-induced PKC activation constrains 5-HT 7 -induced pMF, rats were pretreated with a PKC inhibitor (Gö6983) followed by spinal 5-HT 2A and 5-HT 7 agonists or vehicle injections. Figure 5A shows representative traces of one animal from each group. PKC inhibition was sufficient to rescue pMF at 90 min after spinal 5-HT 2A and 5-HT 7 co-activation (41 ± 9%; P < 0.05; Fig. 5B ). Neither 5-HT 2A nor 5-HT 7 receptor-induced pMF were affected by PKC inhibition (P < 0.05). No changes in phrenic burst amplitude (Fig. 5B ) or respiratory frequency (Fig. 5C ) were observed after administration of PKC inhibitor in vehicle-treated rats. P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from each group at baseline, and 30, 60 and 90 min after injections are reported in Table 5 .
A possible role for PKCα and PKCβ isoforms in cross-talk inhibition from 5-HT 2A to 5-HT 7 receptorinduced pMF was not supported by our results, as pre-treatment with multiple Gö6976 doses failed to elicit pMF (Fig. 6A) . On the other hand, PKCδ inhibition with 50 μM PKCδi (but not with 25 μM PKCδi) restored pMF at 90 min after spinal 5-HT 2A and 5-HT 7 co-activation (49 ± 16%; P < 0.05; Fig. 6B ). Respiratory frequency, P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from each group at baseline, and 30, 60 and 90 min after injections are reported in Table 6 .
Physiological relevance of Q to S inhibition in S pathway-dependent pLTF
Figure 7(A) shows representative traces of phrenic nerve recordings from rats treated with either vehicle (vehicle + sAIH) or 50 μM PKCδi (PKCδi + sAIH), followed by severe AIH. The magnitude of severe AIH-induced pLTF was significantly higher in PKCδi + sAIH (103 ± 20%) vs. vehicle + sAIH rats (54 ± 11%) 90 min after severe AIH (P < 0.05; Fig. 7C ). Apnoeic (32 ± 2 vs. 37 ± 2 mmHg) and recruitment threshold values (35 ± 1 vs. 40 ± 0.4) were not significantly different between vehicle + sAIH and PKCδi + sAIH rats (P > 0.05). No differences were detected in baseline phrenic burst amplitude between groups (P > 0.05; Fig. 7B ), suggesting PKCδi administration does not have acute effects on phrenic activity.
Short-term hypoxic phrenic responses were similar to previous reports from our laboratory . No significant differences were found between vehicle + sAIH (115 ± 19% from baseline) vs. PKCδi + sAIH rats (116 ± 13% from baseline; Fig. 7D ). At the end of experiments, maximal chemoreceptor stimulation (i.e. F IO 2 : 0.10 and F ICO 2 : 0.07) induced a pronounced increase in phrenic burst amplitude vs. 90 min after severe AIH in both vehicle + sAIH (86 ± 11%) and PKCδi + sAIH J Physiol 597.2 Figure 5 . Pretreatment with the non-selective protein kinase C inhibitor (PKCi; Gö6983) restores phrenic motor facilitation (pMF) after 5-HT 2A and 5-HT 7 co-activation A, representative traces of compressed integrated phrenic burst amplitude from baseline to 90 min after intrathecal injections (closed arrows) of vehicle (n = 6), 5-HT 2A (n = 4), 5-HT 7 (n = 6) or 5-HT 2A + 5-HT 7 agonists (n = 7), in rats with PKCi. Grey dashed line in each trace represents baseline. Open arrows depict 30, 60 and 90 min time points, when blood samples were withdrawn. B, percentage change in integrated phrenic burst amplitude, relative to baseline, at 30, 60 and 90 min after intrathecal drug injections. C, phrenic burst frequency at baseline, and at 30, 60 and 90 min after intrathecal drug injections. * PKCi − 5-HT 2A + 5-HT 7 group different from baseline. # PKCi − 5-HT 2A + 5-HT 7 group different from PKCi -vehicle group. Differences were considered significant at P < 0.05. rats (77 ± 8%; Fig. 7E ). Respiratory frequency, P aCO 2 , P aO 2 , standard base excess and mean arterial pressure from vehicle + sAIH and PKCδi + sAIH groups at baseline, and 30, 60 and 90 min after severe AIH were not different, and are reported in Table 7 .
Discussion
Spinal 5-HT 2A and 5-HT 7 receptors elicit respiratory motor plasticity via distinct intracellular mechanisms. Of considerable interest, administration of a spinal 5-HT 7 receptor antagonist or PKA inhibitor enhances moderate AIH-induced and 5-HT 2 receptor-dependent pLTF, whereas PKA activation undermines the response (Hoffman & Mitchell, 2013) . Subsequent studies confirmed these findings, demonstrating that PKA activity undermines 5-HT 2A agonist-induced pMF . Thus, inhibitory interactions exist between these competing mechanisms of serotonindependent phrenic motor plasticity. We extend these findings by showing that concurrent 5-HT 2A and 5-HT 7 activation abolishes phrenic motor plasticity, and that pMF is again restored by spinal PKA or PKCδ inhibition. New findings here include the demonstration that spinal PKCδ inhibition is sufficient to restore pMF with 5-HT 2A and 5-HT 7 co-activation. Furthermore, spinal PKCδ inhibition was sufficient to enhance an S pathway-dependent, severe AIH-induced form of pMF, highlighting a pivotal role of this isoform in Q to S cross-talk interactions.
NADPH oxidase does not appear to play any role in 5-HT 2A to 5-HT 7 cross-talk inhibition, in striking contrast to our recent report demonstrating that NADPH oxidase underlies cross-talk inhibition from 5-HT 2B to 5-HT 7 receptor-induced pMF . These findings reinforce the idea of mechanistic distinctions in pMF elicited by 5-HT 2A and 5-HT 2B receptors (MacFarlane et al. 2011) , despite the fact that both receptors signal via Gq proteins.
Collectively these results reveal complexity in distinct mechanisms of spinal serotonin-induced phrenic motor plasticity. Because intrathecal drug injections do not specifically target phrenic motor neurons, possible contributions of PKCδ and PKA expressed in cervical spinal interneurons and/or glial cells in mediating inhibitory cross-talk interaction between competing serotonergic pathways cannot be excluded. On the other hand, despite legitimate concerns inherent to targeted pharmacology, accumulating data converge on and point to phrenic motor neurons as the major site of plasticity following intermittent hypoxia (or spinal serotonin/ adenosine receptor activation). For example, many relevant molecules in both the Q and the S pathway appear to be expressed within phrenic motor neurons per se, as shown by targeted downregulation of key molecules via intrapleural siRNA delivery; this approach virtually abolishes both Q and S pathway-dependent plasticity (PKCθ: Devinney et al. 2015; TrkB: Dale et al. 2017; A2A receptors: Seven et al. 2018) , without evidence of knock-down in other cervical spinal cells. There are few compelling data consistent with downstream involvement of other cell types in phrenic motor plasticity to date, aside from clear roles for descending raphe neurons in releasing serotonin and the cells (probably glia) releasing J Physiol 597.2 Table 6 . Physiological variables at baseline and 30, 60 and 90 min after episodic 5-HT 2A + 5-HT 7 injections in animals pretreated with PKC inhibitor (PKCi, Gö6976; experiments from dose-response curve were combined; n = 9), 25 μM PKC delta peptide inhibitor (PKCδi; n = 3) or 50 μM PKC delta peptide inhibitor (PKCδi; n = 5). Values are mean ± SD 
Baseline 1.2 ± 1.7 1.5 ± 0.7 0.1 ± 1.9 30 2.3 ± 1.6 3.1 ± 1.5 2.7 ± 1.4 60 0.7 ± 2.5 1.7 ± 5.1 1.5 ± 1.0 90 0.6 ± 1.1 0.5 ± 2.8 −0.4 ± 1.6 MAP, mmHg
Baseline
40 ± 6 4 8 ± 1 4 0 ± 9 60 39 ± 6 4 6 ± 1 4 3 ± 8 90 42 ± 5 4 6 ± 5 4 2 ± 7 sBE, standard base excess; MAP, mean arterial pressure; RF, respiratory frequency.
adenosine to initiate A2A receptor-dependent phrenic motor facilitation. Through greater understanding of the complex interactions between the Q and S pathways to pMF, we hope to gain greater insight into the biological significance of these duelling pathways. We previously suggested that changes in the balance of pathway activation under different physiological conditions enables emergent properties, such as hypoxia pattern sensitivity (Baker & Mitchell, 2000; Wilkerson et al. 2008; Devinney et al. 2013 Devinney et al. , 2016 Huxtable et al. 2018) and/or metaplasticity (Ling et al. 2001; . For example, 5-HT 2 dominant pLTF following moderate AIH is constrained by coincident A2A receptor and PKA activation Hoffman & Mitchell, 2013) . Conversely, spinal PKCδ activation constrains A2A receptor-induced pLTF following severe AIH (Fig. 7) . In addition, when the activation of both pathways is balanced, phrenic motor Figure 6 . Pretreatment with PKCδi, but not with Gö6976, restores phrenic motor facilitation (pMF) after 5-HT 2A and 5-HT 7 co-activation A, percentage change in integrated phrenic burst amplitude from baseline to 90 min after intrathecal 5-HT 2A + 5-HT 7 agonist injections in rats pretreated with 155 nM (n = 3), 310 nM (n = 3) or 620 nM Gö6976 (n = 3). B, percentage change in integrated phrenic burst amplitude from baseline to 90 min after intrathecal 5-HT 2A + 5-HT 7 agonist injections in rats pretreated with 25 μM (n = 3) or 50 μM PKCδi (n = 5). * 50 μM PKCδi − 5-HT 2A + 5-HT 7 group different from baseline. Differences were considered significant at P < 0.05. plasticity is cancelled, such as following moderate acute sustained (20-25 min) but not moderate AIH (Baker & Mitchell, 2000) . The lack of pLTF following moderate acute sustained hypoxia appears to arise from balanced cross-talk inhibition between 5-HT 2 -and A2A-initiated pathways as pMF is revealed with moderate acute sustained hypoxia and spinal A2A receptor inhibition (Devinney et al. 2016 ). Changes in cross-talk inhibition may underlie other emergent properties, such as enhanced pLTF with intermittent hypoxia preconditioning (Ling et al. 2001; Wilkerson & Mitchell, 2009; , although this hypothesis remains to be rigorously tested.
Figure 7. Pretreatment with PKCδi enhances S pathway-dependent severe AIH-induced pLTF (sAIH)
A, representative traces of compressed integrated phrenic burst amplitude from baseline to 90 min after sAIH in rats primed with vehicle (Vehicle + sAIH, n = 8) or 50 μM PKCδi (PKCδi + sAIH, n = 8). Grey dashed line in each trace represents baseline. B, baseline raw phrenic amplitude in Vehicle + sAIH and PKCδi + sAIH groups. C, percentage change in integrated phrenic burst amplitude; D, hypoxic phrenic response relative to baseline; E, maximal chemoreceptor stimulation (F IO 2 : 0.10 and F ICO 2 : 0.07) relative to 90 min after sAIH in Vehicle + sAIH or PKCδi + sAIH groups. * 50 μM PKCδi + sAIH different from saline + sAIH rats. Differences were considered significant at P < 0.05. 
Effect of 5-HT 2A and 5-HT 7 co-activation on pMF
Both 5-HT 2A and 5-HT 7 receptors are expressed in phrenic motor neurons and independently elicit phrenic motor plasticity via distinct mechanisms when activated alone. When these competing pathways are co-activated, phrenic motor plasticity is no longer observed, a complex feature we have recently come to appreciate. These complex interactions were first suspected based on the bell-shaped pMF dose-response curve to episodic spinal serotonin administration . Whereas low serotonin doses elicit robust phrenic motor plasticity, pMF wanes at high doses because of concurrent 5-HT 2 and 5-HT 7 receptor activation . Subsequent studies demonstrated that PKA activity from S pathway activation suppresses 5-HT 2A -induced pMF (Hoffman & Mitchell, 2013; ; differential responses among Gq-coupled serotonin receptor subtypes (e.g. 5-HT 2B vs 5-HT 2A ) were not evaluated.
Although episodic spinal activation of either 5-HT 2B or 5-HT 2A receptors elicits robust phrenic motor plasticity, most studies targeting intracellular mechanisms of phrenic motor plasticity pertain to moderate AIH-induced, 5-HT 2 -dependent pLTF (Baker-Herman et al. 2004; Dale-Nagle et al. 2010; Devinney et al. 2015) vs. pMF induced by selective 5-HT 2B vs. 5-HT 2A receptor activation. Both 5-HT 2B and 5-HT 2A receptors are Gq protein coupled and, thus, were expected to exert their effects via ERK/MAP kinase signaling; the intracellular signalling cascade must differ in key respects because NADPH oxidase activity is necessary for 5-HT 2B -, but not for 5-HT 2A -induced pMF (MacFarlane et al. 2011) .
Mechanism of inhibition arising from 5-HT 7 receptor activation
Many signalling pathways utilize cAMP-dependent PKA activation, but there is considerable variation among cell types and the initiating stimulus. Although spinal PKA activation alone can be sufficient to elicit pMF , 5-HT 7 receptor-induced PKA activity is not necessary for 5-HT 7 receptor-induced pMF , and in fact constrains 5-HT 2 receptor-dependent, AIH-induced pLTF (Hoffman & Mitchell, 2013) as well as 5-HT 2A receptor-induced pMF . Here, we demonstrate that spinal PKA inhibition restores phrenic motor plasticity with 5-HT 2A and 5-HT 7 co-activation, revealing 5-HT 2 receptor-induced pMF.
There is convincing evidence demonstrating that PKA inhibits 5-HT 2A -induced pMF, although the molecular target of PKA on the Q pathway is unknown. The existence of inhibitory cross-talk from cAMP-activated effectors to ERK-MAP kinase has been documented in other systems, and is orchestrated via PKA-dependent rapidly accelerated fibrosarcoma (RAF) phosphorylation (Wu et al. 1993; Ramstad et al. 2000; Dhillon et al. 2002; Dumaz & Marais, 2005) . Different cAMP binding affinity for PKA vs. exchange protein activated by cAMP (EPAC) enables distinct functional outcomes following Gs protein-coupled 5-HT 7 activation. While PKA is preferentially activated by low cAMP levels (Dostmann & Taylor, 1991) , EPAC activation requires much higher cAMP concentrations (Ponsioen et al. 2004) . Thus, even though the cAMP-dependent EPAC pathway to pMF is compromised, cAMP-dependent PKA activity retains the capacity to constrain 5-HT 2A receptor-induced pMF.
Mechanism of inhibition from 5-HT 2A receptor activation Perim et al. (2018) reported that spinal inhibition of NADPH oxidase activity restores pMF with 5-HT 2B and 5-HT 7 co-activation, highlighting the role of NADPH oxidase in cross-talk inhibition between these receptor subtypes. These experiments drove our initial hypothesis that NADPH oxidase would also mediate 5-HT 2A to 5-HT 7 receptor pathway inhibition. However, we found no evidence to support any role for NADPH oxidase in cross-talk inhibition between these receptors. Intracellular signalling cascades after Gq proteincoupled receptor activation include inositol and diacylglycerol, factors that activate conventional/novel PKC isoforms (Nishizuka, 1984 (Nishizuka, , 1992 . Of particular relevance, they contribute to downstream signalling from Gq protein-coupled 5-HT 2A receptors (Narla et al. 2015) . Although spinal inhibition of the novel PKCθ isoform abolishes 5-HT 2 -dependent AIH-induced phrenic motor plasticity, its magnitude is unaffected by inhibition of many other PKC isoforms (Devinney et al. 2015) . On the other hand, spinal PKC activation with phorbol esters initiates pMF via mechanisms that do not require PKCθ activity, demonstrating that other PKC isoforms induce/regulate phrenic motor plasticity (Devinney & Mitchell, 2018) . Because the drug used here to block cross-talk inhibition from the Q to S pathway (Gö6983) does not block PKCθ, moderate AIH-induced pLTF (Devinney et al. 2015) or 5-HT 2A receptor-induced pMF (Fig. 5) , the PKC isoform constraining 5-HT 7 receptor-induced pMF is not necessary for Q pathway-induced pMF per se (just as PKA is not necessary for the S pathway).
Although some PKC isoforms activate select adenyl cyclase subtypes (Choi et al. 1993; Jacobowitz & Iyengar, 1994; Kawabe et al. 1994) , PKC inhibits Gs protein-coupled receptor-activated adenyl cyclase 6 (Lai et al. 1997; Lin et al. 2002) . At low concentrations, Gö6983 inhibits all conventional and some novel PKC isoforms (Devinney et al. 2015) , and thus different drugs were used to determine the specific PKC isoform constraining 5-HT 7 -induced pMF. PKCα/β inhibition (with dose-response curves) did not restore pMF, indicating that a different PKC isoform gives rise to cross-talk inhibition from 5-HT 2A to 5-HT 7 -induced pMF. Phrenic nerve activity did tend to decrease following spinal PKCα/β inhibition (but not significantly), suggesting possible roles of these isoforms in regulating phrenic nerve activity that could be explored in future studies. Conversely, spinal PKCδ inhibition with 50 μM PKCδi had no apparent effect on baseline phrenic nerve activity, yet revealed pMF with concurrent 5-HT 2A and 5-HT 7 receptor activation; thus, PKCδ and not PKCα/β is the relevant isoform for Q to S pathway cross-talk inhibition.
Physiological relevance of Q to S pathway cross-talk inhibition to pLTF
Moderate AIH to pLTF requires Gq protein-coupled receptor activation, ERK-MAP kinase signalling, BDNF/ TrkB signalling (Baker-Herman et al. 2004) and PKCθ activity within phrenic motor neurons (Devinney et al. . In striking contrast, severe AIH-induced pLTF requires A2A-dependent Gs protein-coupled receptor activation, followed by adenylyl cyclase-dependent signalling Devinney et al. 2016; Agosto-Marlin et al. 2017; Seven et al. 2018) . Because a broad-spectrum serotonin receptor antagonist does not block severe AIH-induced pLTF and may actually potentiate its magnitude , inhibition from the serotonin-dependent Q pathway may constrain the S pathway to phrenic motor plasticity.
Here, we demonstrate that spinal PKCδ inhibition enhances severe AIH-induced pLTF, consistent with our conclusion that 5-HT 2A -dependent PKCδ activation constrains the S pathway to respiratory motor plasticity. Although the role of 5-HT 7 receptors in severe AIHinduced pLTF is unknown, both A2A and 5-HT 7 receptors exert their effects via adenylyl cyclase signalling. Thus, spinal PKCδ probably constrains severe AIH-induced pLTF by inhibiting adenylyl cyclase activity (Lai et al. 1997; Lin et al. 2002) .
Sex steroid hormones influence the neural control of breathing and phrenic motor plasticity (Behan et al. 2003; Zabka et al. 2006) ; however, we do not know if similar mechanisms operate in female rats.
Conclusion
We demonstrate novel molecules that underlie cross-talk interactions between competing mechanisms of phrenic motor plasticity. Using selective drugs to inhibit spinal PKCδ or PKA activity, we identified these kinases as relevant molecules in the bidirectional cross-talk interactions. Understanding complex interactions among distinct cellular mechanisms of phrenic motor plasticity may shed light on emergent properties, such as pattern sensitivity and/or metaplasticity (Devinney et al. 2013; , and may represent novel targets for therapeutic intervention as efficient therapeutic outcomes are more likely if we minimize constraints to respiratory motor plasticity. For example, blocking cross-talk inhibition (see Fig. 8 ) may improve our ability to harness 'low-dose' intermittent hypoxia for therapeutic advantage, improving breathing when confronted with life-threatening neuromuscular disorders such as spinal injury or motor neuron disease (Mitchell, 2007) .
